Having trouble accessing articles? Reset your cache.

Surfaxin lucinactant: Preliminary Phase II data

Preliminary results from an open-label, dose-ranging, North American Phase II trial in 78 evaluable patients

Read the full 153 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE